Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options
If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
On January 9, 2026, shares of Beta Bionics declined sharply in trading, following the company’s disclosure of preliminary fourth-quarter 2025 performance metrics that fell short of market expectations.
The company reported lower-than-anticipated new patient starts for its iLet automated insulin delivery system, prompting investor concerns regarding near-term adoption trends and revenue growth.
On this news, Beta Bionics stock fell roughly $11.85 or 37.04% to close at $20.14, on January 9, 2026.
To learn more about the Beta Bionics investigation, go to www.faruqilaw.com/BBNX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5
